AGM 2023 Questions

[Terroni2105]

I wish to understand the business model. A company incorporates Brainchip’s IP into 10,000 units they produce with the intention of selling those 10,000 units. But … they sell only 1,000 units.

Is BrainChip paid a royalty on the 10,000 unit’s the IP was put in, or the 1,000 units that were sold?

 

[JK200SX]

Surely every company the sales and marketing teams are liaising with now, I would presume, aren't all bound with an NDA's. Assuming this is so, can they provide some incite/information on these other companies they have been working with.

 

[JK200SX]

A number of performance rights shares (I think thats their name) were issued to a number of employees for meeting or exceeding their KPI's. We as shareholders what like to know what these KPI's where as there is currently no translation of this "outstanding" work into sales yet?

 

[Quatrojos]

Why persist with a self-flagellating reluctance to release non-price-sensitive announcements regarding partnerships and technological progress, considering that ASX media releases are relatively cheap, convenient, and accurately targeted to a relevant audience?

 

[BaconLover]

Another question from a shareholder:

''I would be interested to know whether these secrets (NDA) will eventually become public, whether companies using Akida will be announced at some point, or whether this will never be known because companies will only sell our chip as their own and we will then only see it as income''?

 

[Damo4]

More of a statement than a question, but I would love to see some sort of roadmap regarding the technology.
The sales will happen when they happen, but I'm curious if that single slide we share around with akida1000,1500,2000 etc is still relevant.
I noticed no Transformer networks were mentioned for the latest tapeout, but was in their plans.

In question form:
"Could you provide an updated roadmap of Akida progression and a brief explanation of what application each model would be best suited for?"

Also:
"Are there any new software developments in progress for specific use cases? If so what are the applications being explored?"

"Are customers able to license the IP directly, or will they be more likely to be funnelled through Ecosystems such as Arm, Megachips, Renesas, IFS etc

 

[rgupta]

Too early to make future projections imo.
At this stage they'd have may be a slight idea, but it's dangerous to make projections if unsure.

If they make a projection and couldn't keep up with it for whatever reason, market won't take it kindly.

I can understand but if they don't that will be considered as broken promise.
That also means that the progress is much slower than management anticipation.
That also means all those shares( options) issued on meeting target are not accurate or someone in the team is unable to perform as per expectations.
So to me it poses more questions.
Upto now I believe brainchip management is very good and they come out good on their promises. If they don't want to provide us with forward statements that will mean a broken promise.

 

[toasty]

I can understand but if they don't that will be considered as broken promise.
That also means that the progress is much slower than management anticipation.
That also means all those shares( options) issued on meeting target are not accurate or someone in the team is unable to perform as per expectations.
So to me it poses more questions.
Upto now I believe brainchip management is very good and they come out good on their promises. If they don't want to provide us with forward statements that will mean a broken promise.

I think its fair to say that mgt has pretty much kept to the technical development schedule. The inital delay in releasing AKD1000 was to incorporate customer requests so that's understandable and acceptable.

What's less satisfactory is the extending of the commercialisation schedule. Its pretty clear that mgt did not anticipate the lengthy sales cyccle of an innovative new technology that few product developers were in fact ready for. The "broken promises" indicate to me that mgt was overly optimistic in its assessment of time to market. Their seemingly misplaced optimism is perhaps one of the reasons for the lack of detail around sales progress. Who wants to admit they're wrong when they are supposed to be experts in the field..............

Just my randon thoughts............

 

[rgupta]

I think its fair to say that mgt has pretty much kept to the technical development schedule. The inital delay in releasing AKD1000 was to incorporate customer requests so that's understandable and acceptable.

What's less satisfactory is the extending of the commercialisation schedule. Its pretty clear that mgt did not anticipate the lengthy sales cyccle of an innovative new technology that few product developers were in fact ready for. The "broken promises" indicate to me that mgt was overly optimistic in its assessment of time to market. Their seemingly misplaced optimism is perhaps one of the reasons for the lack of detail around sales progress. Who wants to admit they're wrong when they are supposed to be experts in the field..............

Just my randon thoughts............

I don't think management was over bullish. When you look at transactions of PVDM share sale I can tell you he is genuine person. To me it might be the tech slow down but even that should not had effected brn as it is a very new technology.
I am quit sure management will cover the future predictions in the coming AGM.

 

[Dhm]

Perhaps we should draw this thread to the attention of TD and he could create a list of questions to Sean Hehir and others to address on AGM day. Or, maybe this has already been done by others.

 

[BaconLover]

Perhaps we should draw this thread to the attention of TD and he could create a list of questions to Sean Hehir and others to address on AGM day. Or, maybe this has already been done by others.

That's the plan, but I'll wait for a few more days if something comes up I can send 1 email after formatting all questions without double up.

They can either;
- reply to me via email which I will share here on TSE.

- address these on AGM (my preference. This way they can address questions officially to the market and not 2000 shareholders here on TSE).

- or as alwaysgreen suggested, do a podcast with Sean addressing these questions.

 

[robsmark]

How many EAP customers remain?
What is the industry distribution of these EAPs?
When do the EAPs expect to be complete?
When do the NDAs elapse?
How many EAP customers have left the program?

 

[Chris B]

My understanding is Akida IP can only be in Megachips and Renesas products because they have a licence agreement. No other products can be sold until a licence is signed. NDA or Not. And it must be a material announcement on asx. Would this be correct???
Not sure how to frame this question correctly. It would put a lot of rumoured products that we are already in to rest. I've been guilty of this myself..

 

[buena suerte :-)]

That's the plan, but I'll wait for a few more days if something comes up I can send 1 email after formatting all questions without double up.

They can either;
- reply to me via email which I will share here on TSE.

- address these on AGM (my preference. This way they can address questions officially to the market and not 2000 shareholders here on TSE).

- or as alwaysgreen suggested, do a podcast with Sean addressing these questions.

TD will be seeing these posts!!

 

[rgupta]

My understanding is Akida IP can only be in Megachips and Renesas products because they have a licence agreement. No other products can be sold until a licence is signed. NDA or Not. And it must be a material announcement on asx. Would this be correct???
Not sure how to frame this question correctly. It would put a lot of rumoured products that we are already in to rest. I've been guilty of this myself..

That is broad level understanding. And we all assumes the same.
On the other hand EAP and strategic partners can keep on working on the product and if feel satisfied by the end product then either use akida chip or akida ip in the final product by signing a contract.
There may also be a chance that term sheet of IP signing is finalized before EAP and strategic partners start working on the project.
So there is a real possibility that we may get a new product in the market before we get the same from renasas and megachips.

 

[Esq.111]

Morning Chippers,

Another question to put forth..

This issue may have been addressed, if so please disregard.

Concerning our American listed ADR's ( 40:1 ).

Code : BCHPY.

Has the EXTRA cost of purchasing this stock been resolved for American buyers, if not why not as this issue was raised some time ago. Naturally I have forgotten what this extra fee is called.

Non-existent trade in this is somewhat confusing as this was supposed to open us up to a far larger investing audience.

Like I said , this issue may have been resolved.
If one of our American share holders could comment on this issue will help decide if this issue should be put forth to Management , again.

Regards,
Esq.

 

[Cand2it]

Could the management please provide some insights into which area, transportation, healthcare, smarthouses etc. that the company belives are closest to deliver revenue?
(English is not my first language so feel free to rephrase for the AGM)

 

[dippY22]

Morning Chippers,

Another question to put forth..

This issue may have been addressed, if so please disregard.

Concerning our American listed ADR's ( 40:1 ).

Code : BCHPY.

Has the EXTRA cost of purchasing this stock been resolved for American buyers, if not why not as this issue was raised some time ago. Naturally I have forgotten what this extra fee is called.

Non-existent trade in this is somewhat confusing as this was supposed to open us up to a far larger investing audience.

Like I said , this issue may have been resolved.
If one of our American share holders could comment on this issue will help decide if this issue should be put forth to Management , again.

Regards,
Esq.

It has been resolved on some platforms per some posters(Ameritrade ??? ...), and not on others. I trade on Fidelity, a tiny rinky dink operation (I'm obviously JOKING....they are HUGE), and they still have in place the $50 foreign transaction fee that is an annoying $50 toll (fee) that they charge coming (buying) or going (selling) and regardless of the size of the trade. But I invest in BRCHF, as opposed to BCHPY. Vanguard does not allow trading in BRCHF shares any more, as far as I know.

I cannot explain why share volume in BCHPY is almost nonexistent,....and yeah I'd love to hear mgnt address why they think that is, but perhaps low sales to date, a low share price and individual company commercial investment guidelines are all reasons activity has been nonexistent. dippY

 

[Kachoo]

Morning Chippers,

Another question to put forth..

This issue may have been addressed, if so please disregard.

Concerning our American listed ADR's ( 40:1 ).

Code : BCHPY.

Has the EXTRA cost of purchasing this stock been resolved for American buyers, if not why not as this issue was raised some time ago. Naturally I have forgotten what this extra fee is called.

Non-existent trade in this is somewhat confusing as this was supposed to open us up to a far larger investing audience.

Like I said , this issue may have been resolved.
If one of our American share holders could comment on this issue will help decide if this issue should be put forth to Management , again.

Regards,
Esq.

I never had an issue with getting ADR shares in my account cost me 9 dollars a trade. It took a while to accumulate the shares they are thinly traded and purchases affect then end goal.

I think that it's all broker dependant the cost.

 

[MDhere]

Agm question i guess -

Will we ba able to see the Akida trademark on products just like intels trademark? If the product is being powered by Brainchip Akida technology would i be correct that it will at the very least on the packaging?